影像组学在卵巢癌治疗中的研究进展OA北大核心CSTPCD
Research progress of radiomics in the treatment of ovarian cancer
卵巢癌作为妇科最常见的恶性肿瘤之一,具有预后差、易复发的特点,主要原因为其诊断时多已处于晚期、易发生腹膜转移,以及易对一线化疗药物铂类产生耐药.卵巢癌的治疗应更多考虑患者的预后和生存质量,及时诊断并选择合适化疗药物将在延长患者无进展生存期(progression-free survival,PFS)等多个方面使患者受益.影像组学在卵巢癌的治疗方面有着重要价值,近年来多有针对卵巢癌化疗耐药及预后的研究,本综述旨在对卵巢癌的术前预测、化疗反应评估、铂化疗耐药以及预后预测方面的影像组学研究进展进行总结概述,以期指导临床利用影像组学技术来更准确地预测患者疾病进展和治疗效果,从而制订个性化治疗方案,提高患者生存质量.未来的研究将进一步探索多组学数据融合的方法,将影像组学与基因组学、蛋白质组学等相结合,期望本综述可以为科研工作者提供研究方向的参考和启示.
Ovarian cancer,a prevalent malignant gynecological tumor,is often associated with dismal prognosis and high recurrence rates. This is primarily attributed to its late-stage diagnosis,frequent peritoneal metastasis,and the development of resistance to platinum-based chemotherapy,a first-line treatment. In treating ovarian cancer,utmost consideration must be given to the prognosis and quality of life of patients. Timely diagnosis and the selection of appropriate chemotherapy drugs are pivotal in extending progression-free survival (PFS) and enhancing the patient's overall well-being. This review endeavors to encapsulate the advancements in radiomics research pertaining to ovarian cancer's preoperative prediction,assessment of chemotherapy response,platinum chemoresistance,and prognosis prediction. Its objective is to empower clinicians with the knowledge to leverage radiomics technology in more precisely forecasting disease progression and treatment outcomes,ultimately leading to the formulation of personalized treatment plans that optimize patient quality of life. Future research aims to delve deeper into the fusion of multi-omics data,combining radiomics with genomics and proteomics,and this review hopes to serve as a valuable resource and inspiration for researchers in their endeavors.
刘娜;吴慧;刘嘉睿;高凯华;杨姣
内蒙古医科大学附属医院影像诊断科,呼和浩特市,010050
临床医学
卵巢癌影像组学铂化疗耐药预后磁共振成像
ovarian cancerradiomicsplatinum-based chemotherapy resistanceprognosismagnetic resonance imaging
《磁共振成像》 2024 (007)
221-226 / 6
内蒙古自治区自然科学基金(编号:2021MS08026);内蒙古医科大学附属医院重点实验室开放基金(编号:2022NYFYSY006) Natural Science Foundation of Inner Mongolia Autonomous Region(No.2021MS08026);the Open Fund of the Key Laboratory of the Affiliated Hospital of Inner Mongolia Medical University(No.2022NYFYSY006).
评论